Kyverna Therapeutics Inc (KYTX)
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for people with autoimmune diseases. The company’s lead candidate, KYV-101, is an autologous CD19 CAR T-cell therapy being studied for stiff person syndrome, myasthenia gravis, and lupus nephritis, and it is also being developed for multiple sclerosis and systemic sclerosis. Kyverna is advancing additional programs, including KYV-102, an autologous CD19 CAR T-cell candidate designed with whole blood rapid manufacturing, and KYV-201, an allogeneic CD19 CAR T-cell candidate. The company also has a license and collaboration agreement with Intellia Therapeutics to research and develop an allogeneic CD19-directed CAR cell therapy product. Founded in 2018 and formerly known as BAIT Therapeutics, Inc., Kyverna is headquartered in Emeryville, California and its common stock is listed on Nasdaq under the ticker KYTX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KYTX
|
$8.43
|
15.0% Upside
|
Fair
|
$30.40
|
314.7% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-2.9x
|
2.3x
|
—
|
440.2 M
|
247.2 M
|
7.1%
|
58.5%
|
0.7
|
—
|
96.2%
|
